Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New rapid COVID test aims for quick results with a digital passport

NCT ID NCT06917261

Diagnosis Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checked how well a new rapid test, TestNPass, can detect COVID-19 using a nose swab. It involved 400 adults at a hospital in France. The goal was to see if the test is accurate enough to replace slower PCR tests and provide a digital health pass.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

400 people

The number who actually took part.

Started

Apr 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ≥18 years of age * Consulting or hospitalized at the University Hospital of Grenoble Alpes, for whom a SARS-CoV-2 RT-PCR test via nasal swab is considered due to symptoms or context (hospitalization in a double room, ongoing epidemic outbreak) * Having provided informed consent to participate in the study. * Patient having the rights to French social insurance Exclusion Criteria: * Contraindication to nasopharyngeal swabbing: * Anatomical abnormalities or medical conditions: * Severe nasal septum deviation or nasal polyps * History of recent nasal or facial surgery * Severe sinusitis or nasal infections * Bleeding disorders * Extreme sensitivity or phobias related to medical procedures * Participation in an exclusion period of another SARS-CoV-2 performance study: Minors Pregnant or breastfeeding women, Individuals under guardianship or curatorship, Individuals deprived of liberty or involuntarily hospitalized, Individuals under administrative or judicial supervision, Persons unable to provide informed consent * Staff with a hierarchical relationship with the principal investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-CoV-2 infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS-CoV-2 infection

Contacts and locations

Locations

  • University Hospital of Grenoble, emergency department

    Grenoble, 38700, France

  • University Hospital of Grenoble, infectious disease department

    Grenoble, 38700, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.